

Topical Collection

COVID-19 Vaccine Development and Vaccination

Message from the Collection Editors

COVID-19 vaccines significantly reduce the risk of illness or death from the disease. Each vaccine stimulates the immune system to produce antibodies that combat the virus. The vaccines utilize a harmless version of a structure resembling the spike protein found on the surface of the virus. In the United States, the following COVID-19 vaccines are available:

- Pfizer-BioNTech COVID-19 vaccine (2024–2025 formula) for individuals aged 6 months and older.
- Moderna COVID-19 vaccine (2024–2025 formula) for individuals aged 6 months and older.
- Novavax COVID-19 vaccine (2024–2025 formula) for individuals aged 12 years and older.

These vaccines have received emergency use authorization or approval from the U.S. Food and Drug Administration (FDA). This collection on “COVID-19 Vaccine Development and Vaccination” will showcase recent efforts to develop, test, and administer vaccines against SARS-CoV-2.

Collection Editors

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, University of Georgia, Athens, GA 30602, USA

Dr. Scott Anthony

National Institute of Allergy and Infectious Diseases (NIAID), Frederick, MD, USA



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/73952

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).